Oryzon Genomics SA (DE:ORN)
FRANKFURT:ORN
Holding DE:ORN?
Track your performance easily

Oryzon Genomics SA (ORN) Income Statement

0 Followers

Oryzon Genomics SA Income Statement

Last quarter (Q4 2022), Oryzon Genomics SA's total revenue was €0.00, a decrease of ― from the same quarter last year. In Q4, Oryzon Genomics SA's net income was €-2.32M. See Oryzon Genomics SA’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
-€ 0.00€ 0.00€ 0.00€ 0.00€ 0.00
Cost of Revenue
-€ -15.23M€ -9.87M€ -8.99M€ -9.85M€ -6.49M
Gross Profit
-€ 15.23M€ 9.87M€ 8.99M€ 9.85M€ 6.49M
Operating Expense
€ 21.05M€ 20.72M€ 16.88M€ 13.28M€ 13.67M€ 9.43M
Operating Income
€ 1.12M€ -5.49M€ -7.01M€ -4.29M€ -3.82M€ -2.94M
Net Non Operating Interest Income Expense
-€ -1.11M€ -449.85K€ -468.96K€ -755.76K€ -800.43K
Other Income Expense
------
Pretax Income
€ -6.89M€ -6.56M€ -7.18M€ -4.78M€ -4.58M€ -3.71M
Tax Provision
€ -2.47M€ -2.33M€ -2.49M€ -1.38M€ -891.59K€ -2.54M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
€ -4.42M€ -4.23M€ -4.69M€ -3.40M€ -3.68M€ -1.18M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
€ -1.12M€ 5.49M€ 7.01M€ 4.29M€ 3.82M€ 2.94M
Net Income From Continuing And Discontinued Operation
€ -4.42M€ -4.23M€ -4.69M€ -3.40M€ -3.68M€ -1.18M
Normalized Income
€ -4.42M€ -4.11M€ -4.68M€ -3.40M€ -3.68M€ -1.17M
Interest Expense
-€ 1.12M€ 455.57K€ 469.09K€ 772.19K€ 803.77K
EBIT
€ 1.29M€ -5.44M€ -6.72M€ -4.31M€ -3.80M€ -2.91M
EBITDA
€ 1.29M€ -5.27M€ -6.58M€ -4.16M€ -3.65M€ -2.76M
Currency in EUR

Oryzon Genomics SA Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis